Emanuela Sant'Antonio

发表

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

M. Cazzola, T. Barbui, P. Guglielmelli, 2016, American journal of hematology.

Somatic mutations of calreticulin in myeloproliferative neoplasms.

G. Superti-Furga, M. Cazzola, C. Pascutto, 2013, The New England journal of medicine.

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

A. Allegra, A. Alonci, S. Russo, 2011, European journal of haematology.

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms

J. Casanova, L. Arcaini, V. Ferretti, 2022, Blood.

Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies

A. Allegra, A. Bitto, N. Irrera, 2021, Molecules.

Diagnosis and management of prefibrotic myelofibrosis

L. Arcaini, E. Rumi, D. Pietra, 2018, Expert review of hematology.

Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.

M. Griesshammer, T. Barbui, R. Mesa, 2021, The Lancet. Haematology.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

M. Cazzola, C. Pascutto, Nicole C. C. Them, 2014, Blood.

Philadelphia chromosome-negative myeloproliferative neoplasms in younger adults: A critical discussion of unmet medical needs, with a focus on pregnancy.

A. Allegra, C. Botta, E. Sant'Antonio, 2021, Blood reviews.

Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

M. Cazzola, T. Barbui, P. Guglielmelli, 2019, American journal of hematology.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

M. Cazzola, C. Pascutto, D. Colomer, 2014, Blood.

Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice

P. Guglielmelli, M. Maffioli, E. Rumi, 2019, Annals of Hematology.

Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia

M. Cazzola, V. Ferretti, M. Gotti, 2015, Haematologica.

High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

M. Griesshammer, T. Barbui, G. Gaidano, 2016, Leukemia.

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

E. Rumi, D. Pietra, E. Sant'Antonio, 2020, International journal of molecular sciences.

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

M. Breccia, M. Tiribelli, M. Bonifacio, 2019, Bone Marrow Transplantation.

Epigenetic therapy in myelodysplastic syndromes

A. Allegra, A. Alonci, S. Russo, 2010, European journal of haematology.

RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features.

P. Guglielmelli, A. Vannucchi, A. Tefferi, 2020, Blood advances.

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms

M. Cazzola, A. Balduini, G. Barosi, 2015, Leukemia.

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria

M. Cazzola, V. Ferretti, E. Rumi, 2017, Oncotarget.

Genetic Heterogeneity in Chronic Myeloid Leukemia: How Clonal Hematopoiesis and Clonal Evolution May Influence Prognosis, Treatment Outcome, and Risk of Cardiovascular Events.

A. Allegra, C. Musolino, E. Sant'Antonio, 2021, Clinical lymphoma, myeloma & leukemia.

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.

M. Cazzola, C. Pascutto, Nicole C. C. Them, 2014, Blood.

Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.

M. Severgnini, M. Cazzola, C. Pascutto, 2013, Blood.

Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib

M. Cazzola, F. Baldanti, M. Furione, 2020, Hematological oncology.

Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients

M. Cazzola, T. Barbui, P. Guglielmelli, 2015, American journal of hematology.

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance

P. Guglielmelli, M. Breccia, M. Tiribelli, 2022, Current oncology.

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project

P. Guglielmelli, F. Mannelli, A. Vannucchi, 2023, Cancer medicine.

Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors

A. Allegra, A. Alonci, S. Russo, 2011, European Journal of Haematology.

Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)

M. Pirrotta, E. Cencini, A. Fabbri, 2023, Annals of Hematology.

Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network).

S. Moretti, A. Cuccaro, E. Cencini, 2021, American journal of blood research.

Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.

M. Cazzola, C. Pascutto, D. Colomer, 2014, Blood.

Myeloproliferative and lymphoproliferative disorders: State of the art

M. Maffioli, E. Rumi, C. Baratè, 2019, Hematological oncology.

Facing erythrocytosis: Results of an international physician survey

T. Barbui, R. Mesa, M. McMullin, 2019, American journal of hematology.

MYELOID NEOPLASIA JAK2 or CALR mutation status de ﬁ nes subtypes of essential thrombocythemia with substantially different clinical course and outcomes

M. Cazzola, C. Pascutto, Nicole C. C. Them, 2014 .